ADAP Stock Risk & Deep Value Analysis
Adaptimmune Therapeutics PLC
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About ADAP Stock
We analyzed Adaptimmune Therapeutics PLC using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran ADAP through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
ADAP Risk Analysis & Red Flags
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
High
Execution
High
Regulatory
High
Upcoming Risk Events
- 📅
Inability to secure immediate funding/liquidity
- 📅
Forced delisting from major exchange
- 📅
Bankruptcy proceedings and equity wipe-out
- 📅
Competitor advances making existing IP less valuable
Unlock ADAP Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Adaptimmune Therapeutics PLC (ADAP) Do?
Market Cap
$17.15M
Sector
Healthcare
Industry
Biotechnology
Employees
506
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Visit Adaptimmune Therapeutics PLC WebsiteInvestment Thesis
There is no viable investment thesis for Adaptimmune Therapeutics PLC under current conditions. The company faces imminent delisting and bankruptcy due to severe financial distress, a collapsed market cap ($0.00B), and critical non-compliance with SEC filing requirements. The scientific promise of its approved IP is entirely stranded. Any 'investment' would be a pure, extremely high-risk lottery ticket on an improbable last-minute acquisition of its IP at a fire-sale price, likely resulting in minimal to zero recovery for common shareholders.
Is ADAP Stock Undervalued?
Unlock the full AI analysis for ADAP
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
ADAP Price Targets & Strategy
12-Month Target
$0.01
Bull Case
$0.05
Valuation Basis
Highly speculative recovery target based on improbable asset sale value for its approved IP, considering current cash crunch, severe filing delinquency, and high delisting risk. No traditional valuation metrics are applicable.
Entry Strategy
No recommended entry given extreme financial distress, severe regulatory non-compliance, and high probability of permanent capital loss. Avoid.
Exit Strategy
For existing shareholders, immediate exit if any liquidity remains to salvage partial capital. Stop loss at $0.00.
Portfolio Allocation
0% (Avoid entirely due to extreme risk of total capital loss and likely delisting).
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is ADAP Financially Healthy?
Profitability
Net Margin
-260.82%
Return on Equity
-163.73%
EPS
$-0.65
Balance Sheet
Current Ratio
1.52
Quick Ratio
1.29
Does ADAP Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding
Moat Sources
1 Identified
The company's significant intellectual property, including an FDA-approved drug, is being rendered effectively worthless due to the complete failure in commercialization and overwhelming financial distress. Without funding or a viable operational entity, the moat cannot protect market position.
Moat Erosion Risks
- •Insolvency and inability to fund ongoing R&D or commercial efforts
- •Competitor innovation rendering existing IP less valuable over time
- •Loss of key scientific talent due to financial instability
ADAP Competitive Moat Analysis
Sign up to see competitive advantages
ADAP Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bearish/Non-existent. Retail sentiment likely focused on delisting/bankruptcy, with minimal engagement due to extreme price and uncertainty.
Institutional Sentiment
Negative. Mizuho downgraded to Neutral (June 26, 2025) citing solvency concerns. No positive institutional activity or buying trends reported since.
Insider Activity (Form 4)
No specific Form 4 filings reported in last 90 days (post-December 2025). No CEO/CFO activity flagged.
Options Flow
Normal options activity (likely negligible volume given current price, market cap, and high risk profile).
Earnings Intelligence
Next Earnings
Unknown; company is severely delinquent on Q2, Q3, Q4 2025, and Q1 2026 filings. The last reported earnings were Q1 2025 (May 15, 2025).
Surprise Probability
Low. If any reports are ever released, they are expected to show severe financial distress and potential going concern issues.
Historical Earnings Pattern
No recent pattern discernible due to missing reports and extreme price decline; past reactions are irrelevant.
Key Metrics to Watch
Competitive Position
Top Competitor
Immunocore
Market Share Trend
Losing (effectively zero due to commercialization failure and financial collapse).
Valuation vs Peers
Adaptimmune is not meaningfully comparable to peers due to its extreme financial distress, effectively zero market capitalization, and severe regulatory non-compliance. Valuation metrics are N/A for ADAP while peers may trade at high P/S or EV/Sales multiples reflecting clinical potential.
Competitive Advantages
- •FDA-approved afami-cel (Kimmtrak) for uveal melanoma (although commercialization has been disastrous)
- •Proprietary SPEAR T-cell platform technology
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive ADAP Stock Higher?
Near-Term (0-6 months)
- •Delisting notification from exchange (imminent due to missed filings)
- •Bankruptcy filing or restructuring announcement
- •Last-minute, highly dilutive financing attempt (low probability)
- •Desperate asset sale (low probability of significant return to shareholders)
Medium-Term (6-18 months)
- •None identified given imminent financial failure.
Long-Term (18+ months)
- •None identified.
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for ADAP?
- ✓
Any official communication regarding SEC filing status or exchange delisting
- ✓
Public announcement of a substantial new financing round (highly improbable)
- ✓
Formal news of an acquisition or asset sale (unlikely to favor existing shareholders)
Bull Case Analysis
See what could go right with Premium
Competing with ADAP
See how Adaptimmune Therapeutics PLC compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Adaptimmune Therapeutics PLC ADAP | $17.1M | 0.5 | — | $13.7M | -260.8% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
FAQ
What is the DVR Score for Adaptimmune Therapeutics PLC (ADAP)?
As of March 24, 2026, Adaptimmune Therapeutics PLC has a DVR Score of 0.5 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Adaptimmune Therapeutics PLC?
Adaptimmune Therapeutics PLC's market capitalization is approximately $17.1M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Adaptimmune Therapeutics PLC use?
ADAP is the ticker symbol for Adaptimmune Therapeutics PLC. The company trades on the NCM.
What is the risk level for ADAP stock?
Our analysis rates Adaptimmune Therapeutics PLC's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is Adaptimmune Therapeutics PLC's revenue growing?
Adaptimmune Therapeutics PLC has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is ADAP stock profitable?
Adaptimmune Therapeutics PLC has a profit margin of -260.8%. The company is currently unprofitable.
How often is the ADAP DVR analysis updated?
Our AI-powered analysis of Adaptimmune Therapeutics PLC is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on March 24, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for ADAP (Adaptimmune Therapeutics PLC) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.